WallStSmart
EVAX

Evaxion Biotech AS

NASDAQ: EVAX · HEALTHCARE · BIOTECHNOLOGY

$4.41
+3.52% today

Updated 2026-04-30

Market cap
$33.61M
P/E ratio
P/S ratio
4.47x
EPS (TTM)
$-1.00
Dividend yield
52W range
$1 – $12
Volume
0.0M

Evaxion Biotech AS (EVAX) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
-40.7%
Last 4 quarters
Revenue YoY growth
-81.9%
Most recent quarter
EPS YoY growth
+85.7%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+5.6%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+12.7%
2025-11-06
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2025-12-31$-0.01+0.0%$4.78$4.71-1.5%
2025-11-06$0.50+600.0%$5.66$6.38+12.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.01$-0.01+0.0%$22040.00-81.9%
2025-09-30$-0.10$0.50+600.0%$7.49M+148.3%
2025-06-30$-0.45$-1.00-122.2%$37000.00-76.0%
2025-03-31$-0.71$-3.14-345.9%$122000.00+139.8%
2024-12-31$-0.15$-0.07+53.3%$122000.00+67.1%
2024-09-30$-0.31$-0.04+87.1%$3.02M
2024-06-30$-0.39$-0.12+69.2%$154000.00
2024-03-31$-0.56$0.30+153.6%$50881.00
2023-12-31$-1.60$-1.60+0.0%$73000.00
2023-09-30$-0.19$-0.21-10.5%
2023-06-30$-0.21$-0.21+0.0%
2023-03-31$-0.24$-0.24+0.0%

Frequently asked questions

Has Evaxion Biotech AS beaten earnings estimates?
Evaxion Biotech AS has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of -40.7% over the last 3 quarters.
How does EVAX stock react to earnings?
EVAX stock has moved an average of +5.6% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Evaxion Biotech AS's revenue growth rate?
Evaxion Biotech AS reported year-over-year revenue growth of -81.9% in its most recent quarter, with EPS growing +85.7% year-over-year.